Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | CHIEF TECHNICAL OPS OFFICER | July 09, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,299 |
Ending reported balance
After 2026-07-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-09 · Exercise / conversion · Acquired 2,464 · Balance 62,763 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Row 2 · 2026-07-09 · Sale · Disposed 2,464 · Balance 60,299 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $90.00 to $90.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.54 · Expires 2035-01-02 | Direct | 45,036 |
Reported balance
After 2026-07-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-09 · Exercise / conversion · Disposed 2,464 · Balance 45,036 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F3: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 2,899 |
Reported balance
Holding disclosure · report date 2026-07-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,899 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $90.00 to $90.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2018 Filed Jan 5, 2018 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 874 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-18-000018 · wf-form4_151518652790156.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · EVP Research Pharma Ops & Tech 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 5,284 F1 · shares: Restricted stock unit (RSU) award vests in four equal annual installments over four years, commencing on January 3, 2019. Upon vesting, each RSU will convert into one share of the issuer. F2 · balance_after: Includes 1,060 shares acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2017 and 663 shares acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2017. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 23:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 78 | $11.82 | $921.96 |
DisclosureSEC source: 0001070081-17-000045 · wf-form4_148374368411152.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · EVP Research Pharma Ops & Tech 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 2,687 F1 · kind: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 187 RSUs from a January 4, 2016 grant of 750 shares. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 02:49 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 35,000 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001070081-17-000043 · wf-form4_148367095214228.xml · derivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · EVP Research Pharma Ops & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-01-02 F4 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 02:49 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 720 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-17-000043 · wf-form4_148367095214228.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · EVP Research Pharma Ops & Tech 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 2,765 F2 · shares: Restricted stock unit (RSU) award vests in four equal annual installments over four years, commencing on January 3, 2018. Upon vesting, each RSU will convert into one share of the issuer. F3 · balance_after: Includes 750 RSUs (previously reported in Table II), granted on January 4, 2016, which vest in equal installments over four years on each anniversary of the grant date. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 02:49 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-17-000043 · wf-form4_148367095214228.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · EVP Research Pharma Ops & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · shares: Restricted stock award vests in four equal annual installments over four years, commencing on January 3, 2018. Read SEC document |
| September 27, 2016 Filed Sep 27, 2016 20:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,586 | $10.85 Strike: $10.85 | $71,458.10 |
DisclosureSEC source: 0001179110-16-030045 · edgar.xml · derivative · entry 5 Almstead Neil Gregory · CIK 0001578850 · EVP Research Pharma Ops & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,102 Underlying: Common Stock · 6,586 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on May 15, 2013 and vests over four years, with 25% of the shares underlying the option vested on December 31, 2013 and an additional 2.083% of the original number of shares underlying the option vesting monthly thereafter, beginning on January 31, 2014. Read SEC document |
| September 27, 2016 Filed Sep 27, 2016 20:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,414 | $10.85 Strike: $10.85 | $37,041.90 |
DisclosureSEC source: 0001179110-16-030045 · edgar.xml · derivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · EVP Research Pharma Ops & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,898 Underlying: Common Stock · 3,414 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on May 15, 2013 and vests over four years, with 25% of the shares underlying the option vested on May 15, 2014 and an additional 2.083% of the original number of shares underlying the option vesting monthly thereafter, beginning on June 15, 2014. Read SEC document |
| September 27, 2016 Filed Sep 27, 2016 20:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 6,586 | $10.85 | $71,458.10 |
DisclosureSEC source: 0001179110-16-030045 · edgar.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · EVP Research Pharma Ops & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2016 Filed Sep 27, 2016 20:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,414 | $10.85 | $37,041.90 |
DisclosureSEC source: 0001179110-16-030045 · edgar.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · EVP Research Pharma Ops & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.